• 1
    Cancer Research UK. Oesophageal cancer - UK incidence statistics. Available at: Accessed October 14, 2008.
  • 2
    Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008; 100: 1184-1187.
  • 3
    Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008; 26: 4551-4556.
  • 4
    Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281: 1623-1627.
  • 5
    Suntharalingam M, Moughan J, Coia LR, et al. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol. 2005; 23: 2325-2331.
  • 6
    Suntharalingam M, Moughan J, Coia LR, et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2003; 56: 981-987.
  • 7
    Pereira B, Gourgou-Bourgade S, Azria D, Ychou M. Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question? J Clin Oncol. 2008; 26: 5133-5134.
  • 8
    Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26: 1086-1092.
  • 9
    Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001; 19: 305-313.
  • 10
    Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337: 161-167.
  • 11
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335: 462-467.
  • 12
    Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003; 125: 1103-1113.
  • 13
    Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006; 7: 644-651.
  • 14
    Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008; 452: 553-563.
  • 15
    Sawyers CL. The cancer biomarker problem. Nature. 2008; 452: 548-552.
  • 16
    van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008; 452: 564-570.
  • 17
    Luthra MG, Ajani JA, Izzo J, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007; 13: 912-919.
  • 18
    Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006; 24: 259-267.
  • 19
    Hildebrandt MAT, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcome in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009; 27: 857-871.
  • 20
    Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006; 24: 3789-3798.
  • 21
    Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008; 14: 2012-2018.
  • 22
    Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus. 2006; 19: 433-442.
  • 23
    Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007; 34: 878-883.
  • 24
    Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000; 18: 3202-3210.
  • 25
    Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006; 24: 4692-4698.
  • 26
    Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19: 3058-3065.
  • 27
    Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004; 22: 900-908.
  • 28
    Erasmus JJ, Munden RF, Truong MT, et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006; 1: 478-486.
  • 29
    Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8: 797-805.
  • 30
    Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004; 101: 1776-1785.
  • 31
    Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001; 233: 300-309.
  • 32
    Brucher BL, Swisher SG, Königsrainer I, et al. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol. 2009; 16: 878-886.
  • 33
    Murthy SB, Patnana SV, Xiao L, et al. The standardized uptake value of 18-fluoro-deoxy glucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. In press.
  • 34
    Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998; 85: 1457-1459.
  • 35
    Kelloff GJ, Sullivan DM, Wilson W, et al. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007; 14: 330-339.
  • 36
    Shankar LK, Sullivan DC. PET/CT in cancer patient management. Commentary. J Nucl Med. 2007; 48( suppl 1): 1S.
  • 37
    Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006; 47: 1059-1066.
  • 38
    Mantel N. Evaluation of survival data and two new rank order statistics arising in ints consideration. Cancer Chemother Rep. 1996; 60: 163-170.
  • 39
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187-220.
  • 40
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 41
    Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009; 22: 1-8.
  • 42
    Siewert JR, Sendler A, Stein HJ. Esophageal cancer: surgical approach. In: MarkmanM, ed. Atlas of Cancer. Philadelphia: Current Medicine Group of Springer Science; 2007: 211-220.
  • 43
    Ajani JA, Barthel JS, Bekaii-Saab T, et al. Esophageal cancer. J Natl Compr Canc Netw. 2008; 6: 818-849.